Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R; Translational Breast Cancer Research Consortium (TBCRC).
O'Donnell PH, et al. Among authors: dees ec.
Breast Cancer Res Treat. 2020 Jun;181(3):623-633. doi: 10.1007/s10549-020-05603-8. Epub 2020 May 6.
Breast Cancer Res Treat. 2020.
PMID: 32378051